FRANKFURT, Germany (Reuters) — Bayer and BASF all but ruled out pursuing new genetic plant breeding methods at home after the European Union ruled the technology should be regulated like genetically modified organisms.
The European Court of Justice (ECJ) said July 25 that gene-editing methods such as CRISPR/Cas9, which can rearrange targeted bits of DNA, fall under rules that now apply to genetic modification via strands of DNA from a different species.
“As we run a global platform, it would mean that basically these applications of these instruments would not be used in Europe and Germany. So overall, that does not impact us as a company too much, but as a European, I’m worried about what that means to the Europeans,” BASF chief executive officer Martin Brudermueller told analysts in a call July 27.
Read Also
Farming Smarter receives financial boost from Alberta government for potato research
Farming Smarter near Lethbridge got a boost to its research equipment, thanks to the Alberta government’s increase in funding for research associations.
BASF in 2012 moved its plant research operations to the United States from Germany in frustration over regulatory proceedings in Europe but this year it agreed to buy most of Bayer’s seed business, including some German-based genetic research operations.
Bayer, taking the No.1 spot in the global seeds and pesticides market with the purchase of Monsanto, also ruled out trying to bring gene-edited crops based on mutagenesis to European markets.
A company spokesperson referred to a statement that CEO Werner Baumann made after signing the Monsanto deal, vowing the combined group would not develop genetically modified crops for commercial use in Europe.
Following the ECJ verdict, the company has widened the definition of “genetically modified” accordingly to include gene editing, the spokesperson said.
Few, if any, commercial ventures based on gene editing have been launched so far in Europe, and only large players were seen as likely to pioneer product development, industry analysts say.
The ECJ ruling will translate into near-prohibitive overhead costs of market access, meaning that smaller players can be ruled out from taking the challenge, they added.
Legal uncertainty before the ruling previously limited work on gene-edited plants to early-stage research and discouraged the launch of commercial applications in Europe.
The verdict was widely condemned by biotech and chemical industry associations, as well as academic scientists, but drew praise from environmental and consumer rights groups.
Germany’s KWS Saat, the world’s largest supplier of sugar beet seeds, said it would study the ruling before making any changes to its strategy.
A spokesperson for Swiss-based seeds and pesticides maker Syngenta, owned by ChemChina, referred to a statement from the European Seed Association saying much of the potential of these innovative methods would likely be lost for Europe.
Proponents of gene editing argue the method can be seen as equivalent to conventional breeding but many times faster.
